2 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow HCV Infection: new trials by email Literature Review of HCV Infection trials Research Report on HCV Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection SOF+DCV+CDI-31244, SOF+DCV+CDI-31244+ASV - HCV Infection | Phase 2 | Withdrawn | Humanity & Health Medical Group Limited | 2019-05-01 | 2020-05-07 |
Hepatitis C (2) · Hepatitis C, Chronic (1)
Blood-Borne Infections (2) · Communicable Diseases (2) · Digestive System Diseases (2) · Flaviviridae Infections (2) · Hepatitis (2) · Hepatitis, Viral, Human (2) · Infections (2) · Liver Diseases (2) · RNA Virus Infections (2) · Virus Diseases (2) · Chronic Disease (1) · Disease Attributes (1) · Hepatitis, Chronic (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
AT-511 (1)
Atea Pharmaceuticals, Inc. (1) · Humanity & Health Medical Group Limited (1)
Belgium (1) · Hong Kong (1)
Georg Lau, MD (1) · Xiao-Jian Zhou (1)
2019 (1)